Navigation Links
Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
Date:4/9/2008

the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

The principal investigators are Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, and Dr. Geoff Hall of St. James's Hospital in Leeds, U.K.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. combination REOLYSIN(R) and carboplatin/paclitaxel clinical trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent
2. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
3. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
4. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
5. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
6. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
7. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
8. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
9. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
10. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
11. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 Aethlon Medical, Inc. (OTC Bulletin ... Schorey and Dr. Wayne Comper have ... Inc. (ESI). Both Dr. Schorey and Dr. Comper ... a wholly owned subsidiary of Aethlon Medical, was ... Hemopurifier®, a medical device being advanced as an ...
(Date:12/15/2009)... BRIARCLIFF MANOR, N.Y., Dec. 15 The ... announced that the professional society is continuing to ... is being held in Arlington, VA, April 19-21, ... society is encouraging non-members to join the organization ... event. The submission deadline is 12 AM EST, ...
(Date:12/15/2009)... , - ... the Ability of,Cardiopoietic Cells to Restore Cardiac Function ... leading Belgian biotechnology company specialising,in cell-based therapies for ... has completed, two months ahead of schedule,enrolment in ... trial of C-Cure, a,unique stem cell therapy for ...
(Date:12/14/2009)... Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic") announced ... The Scripps Research Institute ("Scripps") by entering into ... of Dyadic,s patented and proprietary C1 fungus ("C1"). ... successful relationship between the two organizations which began ... annotate the C1 genome for the first time. ...
Breaking Biology Technology:Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5
... II still video system , Optimized Imaging ... Dye , Michelle Cayouette Jane Moores ,Stratagene Cloning ... filter with all Eagle,Eye II still video ... a single filter specifically designed,for ethidium bromide may be ...
... DNA polymerase results in greater specificity and sensitivity ... Borns Brad Scott Holly Hogrefe , ... DNA polymerase * , is the best ... long, , complex, low-copy number, or GC-rich templates. We ...
... Epitope-Tagging Vectors for Functional Analysis in Yeast ,,, ... , Quinn Lu Tanya Hosfield ... epitope-tagging vectors to express,and functionally analyze eukaryotic genes ... pESC vectors contains one of four different yeast,selective ...
Other Biology Technology:Optimized Imaging of Protein Gels Stained with Coomassie,Brilliant Blue Dye 2Optimized Imaging of Protein Gels Stained with Coomassie,Brilliant Blue Dye 3Optimized Imaging of Protein Gels Stained with Coomassie,Brilliant Blue Dye 4The Best Enzyme for the Toughest PCR Challenges Improved with New Hot-Start Feature 2The Best Enzyme for the Toughest PCR Challenges Improved with New Hot-Start Feature 3Epitope-Tagging Vectors for Functional Analysis in Yeast 2Epitope-Tagging Vectors for Functional Analysis in Yeast 3Epitope-Tagging Vectors for Functional Analysis in Yeast 4Epitope-Tagging Vectors for Functional Analysis in Yeast 5Epitope-Tagging Vectors for Functional Analysis in Yeast 6
(Date:12/15/2009)... Springer has just signed an agreement with the British ... an affiliation with the journal Biogerontology for ... will appoint one member of the Biogerontology ... issue annually. Springer will sponsor the society and ... Biogerontology on www.springerlink.com . , Biogerontology ...
(Date:12/15/2009)... December 2009 - Scientists at VIB and Ghent University ... the treatment of septic shock, the major cause of ... of nitric oxide (NO) gas in mice with septic ... the animal,s organs showed much less damage, while their ... expectations, since it is generally assumed that nitric oxide ...
(Date:12/15/2009)... 2006, a team of Spanish and American researchers found the ... Bonares, Huelva. Now they have published, for the first time, ... with the death of the young cetacean, possibly a baleen ... first discovery of the partial fossil remains of a whale ... Huelva Sands sedimentary formation, but it is the first time ...
Breaking Biology News(10 mins):Septic shock: Nitric oxide beneficial after all 2Story of 4.5 million-year-old whale unveiled in Huelva 2Story of 4.5 million-year-old whale unveiled in Huelva 3Weight Loss Surgery Breaks Families Obesity Cycle 55987 1Weight Loss Surgery Breaks Families Obesity Cycle 55987 2PTC Therapeutics Announces Celgene Exercised Option to Drug Discovery Collaboration 13793 1PTC Therapeutics Announces Celgene Exercised Option to Drug Discovery Collaboration 13793 2Transdel Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 55981 1Transdel Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 55981 2
... 2007 Nanobiosym Inc., announced today that it has ... the United States Defense Threat Reduction Agency (DTRA), a ... of this award were selected after an intense competition ... and industrial labs. , Nanobiosym, and its commercial ...
... SEPTEMBER 27, 2007 New protocol and software developments are ... by making it easier for growers to use previously ... , Historically, gaps between researchers and producers, as ... relevant decisions, have all contributed to data languishing on ...
... and extraordinary $22 million gift to the University of Michigan ... one with a mission of supporting fundamental research to ... a broad range of human diseases. , The A. Alfred ... School, is named for the retail pioneer whose funding and ...
Other Biology News:Nanobiosym awarded $2 million DTRA contract 2Emphasizing the 'precision' in precision agriculture 2$22 million gift from Alfred Taubman launches new biomedical research institute 2$22 million gift from Alfred Taubman launches new biomedical research institute 3$22 million gift from Alfred Taubman launches new biomedical research institute 4
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... reagent has been developed for use ... reduction of nonspecific background staining due ... describe blocking peroxidase with hydrogen peroxide. ... in combination with additional novel components ...
Biology Products: